Xenon Pharmaceuticals Inc.
XENE
$37.11
-$0.40-1.07%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -30.22% | 0.97% | -4.61% | -8.40% | -20.85% |
| Total Depreciation and Amortization | -4.10% | 4.11% | -5.38% | 4.37% | 9.39% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 15.32% | 76.08% | -28.66% | -27.24% | 129.84% |
| Change in Net Operating Assets | 121.51% | -657.31% | 340.18% | -109.30% | 264.67% |
| Cash from Operations | -4.19% | -13.36% | -6.33% | -64.19% | 32.55% |
| Capital Expenditure | -265.12% | 94.51% | -32.71% | 61.03% | -705.32% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 138.52% | -65.20% | 3,763.27% | -97.68% | 357.43% |
| Cash from Investing | 138.37% | -64.97% | 4,874.90% | -98.19% | 352.80% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -94.35% | -90.51% | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -94.35% | -90.51% | -- | -- | -- |
| Foreign Exchange rate Adjustments | 1,087.50% | 94.47% | -2,242.59% | 126.73% | 44.96% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 171.86% | -147.29% | 212.17% | -163.10% | 186.73% |